A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy

Polatuzumab vedotin (PV) is an antibody–drug conjugate targeting CD79b that is approved for patients with relapsed/refractory large B-cell lymphoma (LBCL). Patients who relapse after chimeric antigen receptor (CAR) T-cell therapy were not included in the registration study, and reports of PV use aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Gouni, Sushanth, Rosenthal, Allison C., Crombie, Jennifer L., Ip, Andrew, Kamdar, Manali K., Hess, Brian, Feng, Lei, Watson, Grace, Ayers, Amy, Neelapu, Sattva S., Khurana, Arushi, Lin, Yi, Iqbal, Madiha, Merryman, Reid W., Strati, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092406/
https://www.ncbi.nlm.nih.gov/pubmed/35240681
http://dx.doi.org/10.1182/bloodadvances.2021006801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092406/
https://www.ncbi.nlm.nih.gov/pubmed/35240681
http://dx.doi.org/10.1182/bloodadvances.2021006801

Ejemplares similares